{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:14:37Z","timestamp":1791461677489,"version":"4.3.4"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10787-025-01832-9","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:23:11Z","timestamp":1751523791000},"page":"4997-5009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Parkinson\u2019s disease: genetics and neuroinflammatory insights"],"prefix":"10.1007","volume":"33","author":[{"given":"Isha","family":"Chandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-0962","authenticated-orcid":false,"given":"Rahul","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"1\u20132","key":"1832_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289(1\u20132):18\u201322","journal-title":"J Neurol Sci"},{"issue":"2","key":"1832_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","volume":"129","author":"S Amor","year":"2010","unstructured":"Amor S et al (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154\u2013169","journal-title":"Immunology"},{"issue":"1","key":"1832_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfy219","volume":"166","author":"FL Anderson","year":"2018","unstructured":"Anderson FL et al (2018) Inflammasomes: an emerging mechanism translating environmental toxicant exposure into neuroinflammation in Parkinson\u2019s disease. Toxicol Sci 166(1):3\u201315","journal-title":"Toxicol Sci"},{"key":"1832_CR4","doi-asserted-by":"crossref","unstructured":"Anderson KM, Mosley RL (2016) Therapeutic strategies in neurodegenerative diseases, in Neuroimmune Pharmacology. Springer, pp. 681\u2013711","DOI":"10.1007\/978-3-319-44022-4_42"},{"issue":"8","key":"1832_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11910-022-01207-5","volume":"22","author":"G Arena","year":"2022","unstructured":"Arena G et al (2022) Neurodegeneration and neuroinflammation in Parkinson\u2019s disease: a self-sustained loop. Curr Neurol Neurosci Rep 22(8):427\u2013440","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"19","key":"1832_CR6","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/molecules25194382","volume":"25","author":"S Aryal","year":"2020","unstructured":"Aryal S et al (2020) The pathology of Parkinson\u2019s disease and potential benefit of dietary polyphenols. Molecules 25(19):4382","journal-title":"Molecules"},{"issue":"4","key":"1832_CR7","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba M et al (1998) \u2018Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am J Pathol 152(4):879","journal-title":"Am J Pathol"},{"issue":"8","key":"1832_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mds.28628","volume":"36","author":"PA Barbuti","year":"2021","unstructured":"Barbuti PA et al (2021) Recent advances in the development of stem-cell-derived dopaminergic neuronal transplant therapies for Parkinson\u2019s disease. Mov Disord 36(8):1772\u20131780","journal-title":"Mov Disord"},{"key":"1832_CR9","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s00018-019-03203-4","volume":"76","author":"AN Bayne","year":"2019","unstructured":"Bayne AN, Trempe J-F (2019) Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond. Cell Mol Life Sci 76:4589\u20134611","journal-title":"Cell Mol Life Sci"},{"key":"1832_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T et al (2021) Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Trans Neurodegener 10:1\u201313","journal-title":"Trans Neurodegener"},{"issue":"12","key":"1832_CR11","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1093\/brain\/awh666","volume":"128","author":"D Berg","year":"2005","unstructured":"Berg D et al (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson\u2019s disease. Brain 128(12):3000\u20133011","journal-title":"Brain"},{"key":"1832_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00441-018-2817-y","volume":"373","author":"KJ Billingsley","year":"2018","unstructured":"Billingsley KJ et al (2018) Genetic risk factors in Parkinson\u2019s disease. Cell Tissue Res 373:9\u201320","journal-title":"Cell Tissue Res"},{"key":"1832_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2016.04.015","volume":"100","author":"B Bingol","year":"2016","unstructured":"Bingol B, Sheng M (2016) Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond. Free Radical Biol Med 100:210\u2013222","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"1832_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/neurosci5010005","volume":"5","author":"D Brash-Arias","year":"2024","unstructured":"Brash-Arias D et al (2024) The role of astrocytes and alpha-synuclein in Parkinson\u2019s disease: a review. NeuroSci 5(1):71\u201386","journal-title":"NeuroSci"},{"key":"1832_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F (2018) Mechanisms of \u03b1-synuclein induced synaptopathy in Parkinson\u2019s disease. Front Neurosci 12:80","journal-title":"Front Neurosci"},{"issue":"6","key":"1832_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/jmg.2008.063917","volume":"46","author":"J Brooks","year":"2009","unstructured":"Brooks J et al (2009) Parkin and PINK1 mutations in early onset Parkinson\u2019s disease: comprehensive screening in publicly available cases and control. J Med Genet 46(6):375\u2013381","journal-title":"J Med Genet"},{"key":"1832_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin P, Dave KD, Kordower JH (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298:225\u2013235","journal-title":"Exp Neurol"},{"key":"1832_CR18","unstructured":"Brunialti EAS (2021) \u2018Beta-glucocerebrosidase mediates microglial neuroprotective functions: a possible link between Parkinson\u2019s and Gaucher\u2019s diseases"},{"key":"1832_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fneur.2019.00122","volume":"10","author":"E Caggiu","year":"2019","unstructured":"Caggiu E et al (2019) Inflammation, infectious triggers, and Parkinson\u2019s disease. Front Neurol 10:122","journal-title":"Front Neurol"},{"issue":"3","key":"1832_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P et al (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176","journal-title":"Cell Death Dis"},{"key":"1832_CR21","first-page":"4318416","volume":"1","author":"CL Camp\u00ealo","year":"2017","unstructured":"Camp\u00ealo CL Silva RH (2017) Genetic variants in SNCA and the risk of sporadic Parkinson\u2019s disease and clinical outcomes: a review. Parkinson\u2019s disease 1:4318416","journal-title":"Parkinson\u2019s disease"},{"issue":"8","key":"1832_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2174\/0118715273258646230920074421","volume":"23","author":"P Chhabra","year":"2024","unstructured":"Chhabra P et al (2024) \u2018Pre-clinical aspects and contemporary treatments of Parkinson\u2019s disease. CNS Neurol Disorders Drug Targets CNS Neurolo Disorders 23(8):996\u20131014","journal-title":"CNS Neurol Disorders Drug Targets CNS Neurolo Disorders"},{"key":"1832_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntt.2022.107124","volume":"94","author":"S Chib","year":"2022","unstructured":"Chib S, Singh S (2022) Manganese and related neurotoxic pathways: a potential therapeutic target in neurodegenerative diseases. Neurotoxicol Teratol 94:107124","journal-title":"Neurotoxicol Teratol"},{"issue":"1","key":"1832_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41531-024-00804-0","volume":"10","author":"AD Currie","year":"2024","unstructured":"Currie AD, Wong JK, Okun MS (2024) A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease. NPJ Parkinson\u2019s Disease 10(1):195","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"1","key":"1832_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-024-05419-5","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai L et al (2024) Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies. Cell Mol Life Sci 81(1):1\u201319","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1832_CR26","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3390\/ijms24032477","volume":"24","author":"JS Deyell","year":"2023","unstructured":"Deyell JS et al (2023) The Interplay between \u03b1-Synuclein and Microglia in \u03b1-Synucleinopathies. Int J Mol Sci 24(3):2477","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1832_CR27","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/jcm12134427","volume":"12","author":"L di Biase","year":"2023","unstructured":"di Biase L et al (2023) Levodopa-induced dyskinesias in Parkinson\u2019s disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions. J Clin Med 12(13):4427","journal-title":"J Clin Med"},{"issue":"8","key":"1832_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009258","volume":"2","author":"DW Dickson","year":"2012","unstructured":"Dickson DW (2012) Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2(8):a009258","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1832_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-5960-2-1","volume":"2","author":"KJ Doorn","year":"2014","unstructured":"Doorn KJ et al (2014) Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson\u2019s disease patients. Acta Neuropathol Commun 2:1\u201317","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1832_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ijnp\/pyu103","volume":"18","author":"J Drouin-Ouellet","year":"2015","unstructured":"Drouin-Ouellet J et al (2015) Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson\u2019s disease. Int J Neuropsychopharmacol 18(6):103","journal-title":"Int J Neuropsychopharmacol"},{"key":"1832_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko N et al (2017) Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol 133:303\u2013319","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1832_CR32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/npp.2012.255","volume":"38","author":"P Edison","year":"2013","unstructured":"Edison P et al (2013) Microglia, amyloid, and glucose metabolism in Parkinson\u2019s disease with and without dementia. Neuropsychopharmacology 38(6):938\u2013949","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"1832_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jalz.2014.06.016","volume":"11","author":"Z Fan","year":"2015","unstructured":"Fan Z et al (2015) Influence of microglial activation on neuronal function in Alzheimer\u2019s and Parkinson\u2019s disease dementia. Alzheimer\u2019s Dementia 11(6):608\u2013621","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1832_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2017.07.004","volume":"261","author":"C-H Fan","year":"2017","unstructured":"Fan C-H et al (2017) Ultrasound targeted CNS gene delivery for Parkinson\u2019s disease treatment. J Control Release 261:246\u2013262","journal-title":"J Control Release"},{"key":"1832_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/bs.irn.2019.06.014","volume":"146","author":"T Fern\u00e1ndez-Valle","year":"2019","unstructured":"Fern\u00e1ndez-Valle T, Gabilondo I, G\u00f3mez-Esteban JC (2019) New therapeutic approaches to target alpha-synuclein in Parkinson\u2019s disease: the role of immunotherapy. Int Rev Neurobiol 146:281\u2013295","journal-title":"Int Rev Neurobiol"},{"key":"1832_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-018-0860-4","volume":"18","author":"Z Gan-Or","year":"2018","unstructured":"Gan-Or Z, Liong C, Alcalay RN (2018) GBA-associated Parkinson\u2019s disease and other synucleinopathies. Curr Neurol Neurosci Rep 18:1\u201310","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"1832_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JPD-150630","volume":"5","author":"S George","year":"2015","unstructured":"George S, Brundin P (2015) Immunotherapy in Parkinson\u2019s disease: micromanaging alpha-synuclein aggregation. J Parkinson\u2019s Dis 5(3):413\u2013424","journal-title":"J Parkinson\u2019s Dis"},{"key":"1832_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnmol.2014.00032","volume":"7","author":"BK Gilsbach","year":"2014","unstructured":"Gilsbach BK, Kortholt A (2014) Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci 7:32","journal-title":"Front Mol Neurosci"},{"key":"1832_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0176-9","volume":"2","author":"RM Gir\u00e1ldez-P\u00e9rez","year":"2014","unstructured":"Gir\u00e1ldez-P\u00e9rez RM et al (2014) Models of \u03b1-synuclein aggregation in Parkinson\u2019s disease. Acta Neuropathol Commun 2:1\u201317","journal-title":"Acta Neuropathol Commun"},{"issue":"13","key":"1832_CR40","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/mds.25639","volume":"28","author":"Group PS","year":"2013","unstructured":"Group PS (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson\u2019s disease (STEADY-PD). Movem Disord 28(13):1823\u20131831","journal-title":"Movem Disord"},{"issue":"4","key":"1832_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.37349\/ent.2023.00048","volume":"3","author":"G Henriquez","year":"2023","unstructured":"Henriquez G, Narayan M (2023) Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease. Explor Neuroprot Ther 3(4):207\u2013234","journal-title":"Explor Neuroprot Ther"},{"issue":"1","key":"1832_CR42","first-page":"403039","volume":"11","author":"S Hisahara","year":"2011","unstructured":"Hisahara S, Shimohama S (2011) Dopamine receptors and Parkinson\u2019s disease. Int J Med Chem 11(1):403039","journal-title":"Int J Med Chem"},{"issue":"1","key":"1832_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2012.07.002","volume":"19","author":"S Iannaccone","year":"2013","unstructured":"Iannaccone S et al (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson\u2019s disease. Parkinsonism Relat Disord 19(1):47\u201352","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"1832_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795\u2013808","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1832_CR45","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J et al (2018) Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75(10):1206\u20131214","journal-title":"JAMA Neurol"},{"key":"1832_CR46","unstructured":"Jayadev Menon P (2024) Genotype-phenotype correlation in PRKN-associated Parkinson\u2019s disease"},{"issue":"10","key":"1832_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tips.2011.06.001","volume":"32","author":"S Kawajiri","year":"2011","unstructured":"Kawajiri S et al (2011) Genetic mutations and functions of PINK1. Trends Pharmacol Sci 32(10):573\u2013580","journal-title":"Trends Pharmacol Sci"},{"key":"1832_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt231","volume":"6","author":"WS Kim","year":"2014","unstructured":"Kim WS, K\u00e5gedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimer\u2019s Res Ther 6:1\u20139","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"8","key":"1832_CR49","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3233\/JPD-223380","volume":"12","author":"A Kolicheski","year":"2022","unstructured":"Kolicheski A et al (2022) Early-onset Parkinson\u2019s disease: creating the right environment for a genetic disorder. J Parkinson\u2019s Dis 12(8):2353\u20132367","journal-title":"J Parkinson\u2019s Dis"},{"key":"1832_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO et al (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res 186:106550","journal-title":"Pharmacol Res"},{"key":"1832_CR51","doi-asserted-by":"crossref","unstructured":"Kumar S, Goyal L, Singh S (2022) Tremor and rigidity in patients with Parkinson\u2019s disease: Emphasis on epidemiology, pathophysiology and contributing factors. CNS Neurol Disord Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 21(7):596\u2013609","DOI":"10.2174\/1871527320666211006142100"},{"issue":"5","key":"1832_CR52","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/cells9051115","volume":"9","author":"G Lamonaca","year":"2020","unstructured":"Lamonaca G, Volta M (2020) Alpha-synuclein and LRRK2 in synaptic autophagy: linking early dysfunction to late-stage pathology in Parkinson\u2019s disease. Cells 9(5):1115","journal-title":"Cells"},{"key":"1832_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11481-009-9176-0","volume":"4","author":"J-K Lee","year":"2009","unstructured":"Lee J-K, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson\u2019s disease. J Neuroimmune Pharmacol 4:419\u2013429","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"1832_CR54","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","volume":"125","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Chinen J, Kavanaugh A (2010) Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 125(2):S314\u2013S323","journal-title":"J Allergy Clin Immunol"},{"key":"1832_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101817","volume":"84","author":"J Li","year":"2023","unstructured":"Li J et al (2023) PINK1\/Parkin-mediated mitophagy in neurodegenerative diseases. Ageing Res Rev 84:101817","journal-title":"Ageing Res Rev"},{"issue":"6","key":"1832_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","volume":"64","author":"X Lin","year":"2009","unstructured":"Lin X et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant \u03b1-synuclein. Neuron 64(6):807\u2013827","journal-title":"Neuron"},{"issue":"1","key":"1832_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","volume":"59","author":"B Liss","year":"2019","unstructured":"Liss B, Striessnig J (2019) The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson\u2019s disease. Annu Rev Pharmacol Toxicol 59(1):263\u2013289","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"1832_CR58","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/life11080804","volume":"11","author":"L Magistrelli","year":"2021","unstructured":"Magistrelli L, Contaldi E, Comi C (2021) The impact of snca variations and its product alpha-synuclein on non-motor features of parkinson\u2019s disease. Life 11(8):804","journal-title":"Life"},{"issue":"29","key":"1832_CR59","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR et al (2016) Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons. J Neurosci 36(29):7693\u20137706","journal-title":"J Neurosci"},{"issue":"4","key":"1832_CR60","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neurobiolaging.2005.08.012","volume":"27","author":"KSP McNaught","year":"2006","unstructured":"McNaught KSP, Olanow CW (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging 27(4):530\u2013545","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1832_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","volume":"10","author":"PJ Menon","year":"2024","unstructured":"Menon PJ (2024) Genotype\u2013phenotype correlation in PRKN-associated Parkinson\u2019s disease\u2019. NPJ Parkinson\u2019s Dis 10(1):72","journal-title":"NPJ Parkinson\u2019s Dis"},{"key":"1832_CR62","doi-asserted-by":"publisher","first-page":"852003","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon S et al (2022) Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front Neurol 13:852003","journal-title":"Front Neurol"},{"issue":"13","key":"1832_CR63","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/ijms25137183","volume":"25","author":"M Muleiro Alvarez","year":"2024","unstructured":"Muleiro Alvarez M et al (2024) A comprehensive approach to Parkinson\u2019s disease: addressing its molecular, clinical, and therapeutic aspects. Int J Mol Sci 25(13):7183","journal-title":"Int J Mol Sci"},{"key":"1832_CR64","doi-asserted-by":"crossref","unstructured":"M\u00fcller T (2009) Levodopa\/carbidopa and entacapone in the treatment of Parkinson\u2019s disease: efficacy, safety and patient preference. Patient Preference and Adherence, pp. 51\u201359","DOI":"10.2147\/PPA.S4084"},{"issue":"5","key":"1832_CR65","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/17425255.2020.1750596","volume":"16","author":"T M\u00fcller","year":"2020","unstructured":"M\u00fcller T (2020) Pharmacokinetics and pharmacodynamics of levodopa\/carbidopa cotherapies for Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 16(5):403\u2013414","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1832_CR66","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3389\/fneur.2018.00711","volume":"9","author":"M Muthuraman","year":"2018","unstructured":"Muthuraman M et al (2018) Deep brain stimulation and L-DOPA therapy: concepts of action and clinical applications in Parkinson\u2019s disease. Front Neurol 9:711","journal-title":"Front Neurol"},{"issue":"3","key":"1832_CR67","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2174\/1570159X13666151030104414","volume":"14","author":"A Nardin","year":"2016","unstructured":"Nardin A, Schrepfer E, Ziviani E (2016) Counteracting PINK\/Parkin deficiency in the activation of mitophagy: a potential therapeutic intervention for Parkinson\u2019s disease. Curr Neuropharmacol 14(3):250\u2013259","journal-title":"Curr Neuropharmacol"},{"key":"1832_CR68","doi-asserted-by":"crossref","unstructured":"Nissar S et al (2022) Single Nucleotide Polymorphisms and Parkinson\u2019s Disease Susceptibility. In: Genetic Polymorphism and Disease. CRC Press, pp. 217\u2013231","DOI":"10.1201\/9781003246244-9"},{"issue":"7","key":"1832_CR69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/humu.21277","volume":"31","author":"K Nuytemans","year":"2010","unstructured":"Nuytemans K et al (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763\u2013780","journal-title":"Hum Mutat"},{"key":"1832_CR70","doi-asserted-by":"crossref","unstructured":"Ortiz GG et al (2017) Physiology and pathology of neuroimmunology: Role of inflammation in parkinson\u2019s disease. In: Physiology and Pathology of Immunology. IntechOpen","DOI":"10.5772\/intechopen.70377"},{"key":"1832_CR71","unstructured":"Palmas MF (2023) Neuropathological role of alpha-synuclein: major contribution of inflammation in the evolution of both motor and non-motor symptoms of Parkinson\u2019s disease"},{"key":"1832_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101783","volume":"83","author":"SP Panda","year":"2023","unstructured":"Panda SP et al (2023) Interlinked role of ASN, TDP-43 and Miro1 with parkinopathy: focus on targeted approach against neuropathy in parkinsonism. Ageing Res Rev 83:101783","journal-title":"Ageing Res Rev"},{"issue":"8","key":"1832_CR73","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/mds.22524","volume":"24","author":"N Pankratz","year":"2009","unstructured":"Pankratz N et al (2009) Alpha-synuclein and familial Parkinson\u2019s disease. Mov Disord 24(8):1125\u20131131","journal-title":"Mov Disord"},{"issue":"2","key":"1832_CR74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar M, Grealish S, Henchcliffe C (2020) The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci 21(2):103\u2013115","journal-title":"Nat Rev Neurosci"},{"key":"1832_CR75","unstructured":"Patergnani S et al (2022) \u2018\u7ebf\u7c92\u4f53\u5e94\u6fc0\u53cd\u5e94:\u201c\u5316\u8eab\u535a\u58eb\u201d \u7684\u795e\u7ecf\u5143\u75be\u75c5\u2019, \u4e2d\u56fd\u795e\u7ecf\u518d\u751f\u7814\u7a76 (\u82f1\u6587\u7248), 17(12):2563"},{"issue":"9","key":"1832_CR76","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/M19-2534","volume":"172","author":"PSGS-PIII Investigators","year":"2020","unstructured":"PSGS-PIII Investigators (2020) \u2018Isradipine versus placebo in early Parkinson disease: a randomized trial. Annals Intern Med 172(9):591\u2013598","journal-title":"Annals Intern Med"},{"issue":"1","key":"1832_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s40478-020-01062-w","volume":"8","author":"PMJ Quinn","year":"2020","unstructured":"Quinn PMJ et al (2020) PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol Commun 8(1):189","journal-title":"Acta Neuropathol Commun"},{"key":"1832_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135873","volume":"753","author":"K Raj","year":"2021","unstructured":"Raj K et al (2021) Metals associated neurodegeneration in Parkinson\u2019s disease: Insight to physiological, pathological mechanisms and management. Neurosci Lett 753:135873","journal-title":"Neurosci Lett"},{"issue":"9","key":"1832_CR79","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.3390\/ijms22094956","volume":"22","author":"M Rasheed","year":"2021","unstructured":"Rasheed M et al (2021) Epigenetic regulation of neuroinflammation in Parkinson\u2019s disease. Int J Mol Sci 22(9):4956","journal-title":"Int J Mol Sci"},{"issue":"LRRK2","key":"1832_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-3-319-49969-7_10","volume":"2","author":"HJ Rideout","year":"2017","unstructured":"Rideout HJ, Re DB (2017) LRRK2 and the \u201cLRRKtosome\u201d at the crossroads of programmed cell death: clues from RIP kinase relatives. Leucine-Rich Repeat Kinase 2(LRRK2):193\u2013208","journal-title":"Leucine-Rich Repeat Kinase"},{"issue":"4","key":"1832_CR81","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1523\/JNEUROSCI.1170-17.2017","volume":"38","author":"E Rockenstein","year":"2018","unstructured":"Rockenstein E et al (2018) Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies. J Neurosci 38(4):1000\u20131014","journal-title":"J Neurosci"},{"issue":"3","key":"1832_CR82","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737175.2021.1883428","volume":"21","author":"K Rukavina","year":"2021","unstructured":"Rukavina K et al (2021) Non-motor complications in late stage Parkinson\u2019s disease: recognition, management and unmet needs. Expert Rev Neurother 21(3):335\u2013352","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"1832_CR83","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00044-024-03203-5","volume":"33","author":"N Saini","year":"2024","unstructured":"Saini N et al (2024) Motor and non-motor symptoms, drugs, and their mode of action in Parkinson\u2019s disease (PD): a review. Med Chem Res 33(4):580\u2013599","journal-title":"Med Chem Res"},{"issue":"8064","key":"1832_CR84","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N et al (2025) Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature 641(8064):971\u2013977. https:\/\/doi.org\/10.1038\/s41586-025-08700-0","journal-title":"Nature"},{"issue":"2","key":"1832_CR85","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/mds.26377","volume":"31","author":"A Schneeberger","year":"2016","unstructured":"Schneeberger A, Tierney L, Mandler M (2016) Active immunization therapies for Parkinson\u2019s disease and multiple system atrophy. Mov Disord 31(2):214\u2013224","journal-title":"Mov Disord"},{"issue":"5","key":"1832_CR86","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/mds.27998","volume":"35","author":"SH Seo","year":"2020","unstructured":"Seo SH et al (2020) Replication-based rearrangements are a common mechanism for SNCA duplication in Parkinson\u2019s disease. Mov Disord 35(5):868\u2013876","journal-title":"Mov Disord"},{"key":"1832_CR87","unstructured":"Shirsath V, Bhongade Y (no date) A review: Parkinson\u2019s disease\u2019"},{"issue":"8","key":"1832_CR88","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV (2022) GBA variants and Parkinson disease: mechanisms and treatments. Cells 11(8):1261","journal-title":"Cells"},{"issue":"9","key":"1832_CR89","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13258","volume":"5","author":"B Snyder","year":"2017","unstructured":"Snyder B et al (2017) Chronic intermittent hypoxia induces oxidative stress and inflammation in brain regions associated with early-stage neurodegeneration. Physiol Rep 5(9):e13258","journal-title":"Physiol Rep"},{"issue":"6645","key":"1832_CR90","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG et al (1997) \u03b1-Synuclein in Lewy bodies. Nature 388(6645):839\u2013840. https:\/\/doi.org\/10.1038\/42166","journal-title":"Nature"},{"key":"1832_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"E Srinivasan","year":"2021","unstructured":"Srinivasan E et al (2021) Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med 8:736978","journal-title":"Front Med"},{"key":"1832_CR92","doi-asserted-by":"crossref","unstructured":"Stocchi F et al (2024) \u2018Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol pp. 1\u201313","DOI":"10.1038\/s41582-024-01034-x"},{"key":"1832_CR93","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","volume":"9","author":"SR Subramaniam","year":"2017","unstructured":"Subramaniam SR, Federoff HJ (2017) Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease. Front Aging Neurosci 9:176","journal-title":"Front Aging Neurosci"},{"issue":"8064","key":"1832_CR94","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","volume":"641","author":"V Tabar","year":"2025","unstructured":"Tabar V et al (2025) Phase I trial of hES\u00a0cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature 641(8064):978\u2013983. https:\/\/doi.org\/10.1038\/s41586-025-08845-y","journal-title":"Nature"},{"issue":"6","key":"1832_CR95","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","volume":"16","author":"E-K Tan","year":"2020","unstructured":"Tan E-K et al (2020) Parkinson disease and the immune system\u2014associations, mechanisms and therapeutics. Nat Rev Neurol 16(6):303\u2013318","journal-title":"Nat Rev Neurol"},{"key":"1832_CR96","doi-asserted-by":"publisher","first-page":"971270","DOI":"10.3389\/fnins.2022.971270","volume":"16","author":"P Turski","year":"2022","unstructured":"Turski P et al (2022) Review of the epidemiology and variability of LRRK2 non-p. Gly2019Ser pathogenic mutations in Parkinson\u2019s disease. Front Neurosci 16:971270","journal-title":"Front Neurosci"},{"issue":"115","key":"1832_CR97","doi-asserted-by":"publisher","first-page":"re4","DOI":"10.1126\/scisignal.3115re4","volume":"3","author":"P Vandenabeele","year":"2010","unstructured":"Vandenabeele P et al (2010) The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 3(115):re4\u2013re4","journal-title":"Sci Signal"},{"issue":"7","key":"1832_CR98","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N et al (2021) Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol 20(7):559\u2013572","journal-title":"Lancet Neurol"},{"key":"1832_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Trans Neurodegener 4:1\u20139","journal-title":"Trans Neurodegener"},{"key":"1832_CR100","unstructured":"Wang W-Y et al (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease. Annals Trans Med 3(10)"},{"key":"1832_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105700","volume":"168","author":"F Weiss","year":"2022","unstructured":"Weiss F et al (2022) Immune responses in the Parkinson\u2019s disease brain. Neurobiol Dis 168:105700","journal-title":"Neurobiol Dis"},{"key":"1832_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105908","volume":"76","author":"Q-P Xia","year":"2019","unstructured":"Xia Q-P, Cheng Z-Y, He L (2019) The modulatory role of dopamine receptors in brain neuroinflammation. Int Immunopharmacol 76:105908","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1832_CR103","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/cpt.1374","volume":"105","author":"KE Zeuner","year":"2019","unstructured":"Zeuner KE et al (2019) Progress of pharmacological approaches in Parkinson\u2019s disease. Clin Pharmacol Ther 105(5):1106\u20131120","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1832_CR104","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W et al (2005) Aggregated \u03b1-synuclein activates microglia: a process leading to disease progression in Parkinson\u2019s disease. FASEB J 19(6):533\u2013542","journal-title":"FASEB J"},{"key":"1832_CR105","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2016.11.002","volume":"265","author":"Q-S Zhang","year":"2017","unstructured":"Zhang Q-S et al (2017) Pathological \u03b1-synuclein exacerbates the progression of Parkinson\u2019s disease through microglial activation. Toxicol Lett 265:30\u201337","journal-title":"Toxicol Lett"},{"issue":"1","key":"1832_CR106","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1038\/s41598-019-42286-8","volume":"9","author":"J Zhao","year":"2019","unstructured":"Zhao J et al (2019) Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep 9(1):5790","journal-title":"Sci Rep"},{"issue":"6","key":"1832_CR107","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.parkreldis.2006.12.014","volume":"13","author":"T Ziemssen","year":"2007","unstructured":"Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson\u2019s disease. Parkinsonism Relat Disord 13(6):323\u2013332","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01832-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:02:30Z","timestamp":1758085350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01832-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}